<SEC-DOCUMENT>0001178913-15-003629.txt : 20151202
<SEC-HEADER>0001178913-15-003629.hdr.sgml : 20151202
<ACCEPTANCE-DATETIME>20151202070039
ACCESSION NUMBER:		0001178913-15-003629
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20151202
FILED AS OF DATE:		20151202
DATE AS OF CHANGE:		20151202

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAMADA LTD
		CENTRAL INDEX KEY:			0001567529
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35948
		FILM NUMBER:		151263551

	BUSINESS ADDRESS:	
		STREET 1:		7 SAPIR ST. WEIZMANN SCIENCE PARK
		CITY:			NESS ZIONA
		STATE:			L3
		ZIP:			74140
		BUSINESS PHONE:		97289406472

	MAIL ADDRESS:	
		STREET 1:		7 SAPIR ST. WEIZMANN SCIENCE PARK
		CITY:			NESS ZIONA
		STATE:			L3
		ZIP:			74140
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk1517683.htm
<DESCRIPTION>6-K
<TEXT>
<html>
<head>
    <title>zk1517683.htm</title>
    <!--Licensed to: ZKG-->
    <!--Document Created using EDGARizer 2020 5.5.2.0-->
    <!--Copyright 1995 - 2015 Summit Financial Printing. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">UNITED STATES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 14pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Washington, D.C. 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 14pt; FONT-WEIGHT: bold">FORM 6-K</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Report of Foreign Private Issuer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Pursuant to Rule 13a-16 or 15d-16</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">of the Securities Exchange Act of 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the Month of December, 2015</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Commission File Number 001-35948</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 16pt; FONT-WEIGHT: bold">Kamada Ltd.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Translation of registrant&#8217;s name into English)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">7 Sapir St.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Kiryat Weizmann Science Park</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">P.O Box 4081</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Ness Ziona 74140</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Israel</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;(Address of principal executive offices)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Form 20-F <font style="DISPLAY: inline;" face="Wingdings 2, serif">T</font>&#160;&#160;&#160;Form 40-F <font style="DISPLAY: inline;" face="Wingdings">&#168;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Yes <font style="DISPLAY: inline;" face="Wingdings">&#168;</font>&#160;&#160;&#160;No <font style="DISPLAY: inline;" face="Wingdings 2, serif">T</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If &#8220;Yes&#8221; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-____</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">This Form 6-K is being incorporated by reference into the Registrant&#8217;s Form S-8 Registration Statement File No. 333-192720.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following exhibit is attached:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">99.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;News Release: Kamada Provides Update on Alpha-1 Antitrypsin Development in Newly Diagnosed Type 1 Diabetes</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURE</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -9pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -9pt" align="left">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Date: December 2, 2015</font></div>
</td>
<td align="left" valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">KAMADA LTD.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">By:&#160;&#160;<font style="DISPLAY: inline">/s/ Gil Efron</font></font></div>
</td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Gil Efron</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deputy Chief Executive Officer and Chief Financial Officer</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">EXHIBIT INDEX</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline"><font style="DISPLAY: inline">EXHIBIT NO.</font></font></div>
</td>
<td valign="top" width="75%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline"><font style="DISPLAY: inline">DESCRIPTION</font></font></div>
</td>
</tr><tr>
<td valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="75%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="8%" style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">99.1</font></div>
</td>
<td align="left" valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">News Release: Kamada Provides Update on Alpha-1 Antitrypsin Development in Newly Diagnosed Type 1 Diabetes</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
<head>
    <title>exhibit_99-1.htm</title>
    <!--Licensed to: ZKG-->
    <!--Document Created using EDGARizer 2020 5.5.2.0-->
    <!--Copyright 1995 - 2015 Summit Financial Printing. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Exhibit 99.1</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="50%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">News Release</font></font></div>
</td>
<td width="50%" style="TEXT-ALIGN: right"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<img src="img.jpg" alt=""></font></td>
</tr></table>
</div>

<div>&#160;</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Kamada Provides Update on Alpha-1 Antitrypsin Development in Newly Diagnosed</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;Type 1 Diabetes</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">NESS ZIONA, Israel (December 2, 2015) &#8211; Kamada Ltd. (NASDAQ and TASE: KMDA), </font>a plasma-derived protein therapeutics company focused on orphan indications, announces it will un-blind the current clinical trial of the Company&#8217;s proprietary human Alpha-1 Antitrypsin (AAT) to treat newly diagnosed pediatric and young adult patients with type 1 diabetes (T1D) at the planned interim analysis.&#160;&#160;This change will accelerate the timeline for future commercialization of the product, should the analysis be positive.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This double-blind, placebo-controlled, multicenter clinical trial of pediatric and young adult patients with newly diagnosed T1D is evaluating the safety and efficacy of intravenous AAT to halt disease progression and maintain the ability of the pancreas to produce insulin.&#160;&#160;The study is being conducted at four leading pediatric T1D medical centers in Israel and is evaluating beta cell functioning as measured by C-peptide parameters<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">,</font> glycemic control expressed in HbA1C levels, hypoglycemic events and insulin daily dose, among others<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font> These measurements will be part of the final report.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;The planned interim analysis was intended to establish trial safety and provide futility analysis for approximately 90 patients after one year in the trial, while maintaining the blinding of the trial.&#160;&#160;After thorough examination of the content of such an analysis, we have concluded that the blinded results will not provide us with sufficient information for discussions with potential strategic partners and/or to determine whether to continue with the study. In consultation with our regulatory and clinical advisors, as well as the trial investigators, we have decided to generate the final report based on clinical data from 60 patients who have completed one year of therapy by the end of 2016, with results expected in the first half of 2017,&#8221; stated Amir London, Chief Executive Officer of Kamada.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;We expect to enroll 60 patients in this study by year-end 2015, and have determined that this will be sufficient to allow us to explore the differences between treatment groups without the limitations of the blinding.&#160;&#160;To date the safety profile of AAT is excellent without any major adverse events both in the current trial, which includes pediatric patients, as well as in commercial settings, where the drug has been used to treat hundreds of patients for its U.S. Food and Drug Administration (FDA) approved indication.&#160;&#160;Further, preclinical data regarding the mechanism of action of AAT supports the positive data demonstrated in the Phase 1/2 clinical trial of AAT for the treatment of newly diagnosed T1D,&#8221; stated Eran Schenker, M.D., Kamada&#8217;s Vice President-Medical Director.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;We remain committed to T1D patients and believe AAT offers an exciting opportunity for Kamada to bring a promising therapy to newly diagnosed pediatric and young adult patients.&#160;&#160;Consequently, we have agreed with the clinicians that all patients who complete the current clinical trial will be eligible to continue treatment under an investigator<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font>initiated trial,&#8221; added Dr. Schenker.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;We strongly believe that obtaining the data more than two years sooner than under the original plan will afford us a number of significant advantages, as it will provide data to discuss with potential strategic partners and to plan a pivotal trial. During the past two years we have gained additional noteworthy knowledge on the mechanism of action of AAT that correlates well with our treatment of newly diagnosed T1D, and have consulted with both the FDA and the European Medicine Agency regarding pivotal trial design.&#160;&#160;Subject to successful results in the current trial, we plan to initiate a pivotal study together with strategic partners that would expand the study to other geographies, such as the U.S. and Europe, which would allow us to accelerate product commercialization,&#8221; concluded Mr. London.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In T1D<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">,</font> autoimmune attacks occur on pancreatic beta cells that secrete insulin, thereby compromising insulin level and glycemic control.&#160;&#160;Over time there is progressive deterioration of self-insulin secretion, poor capability to control glucose levels and, eventually, full external insulin dependence.&#160;&#160;By maintaining its ability to produce insulin, the body can independently control glucose level and reduce diabetes complications that result from poor glycemic control (e.g., cardiovascular disease, kidney disease, eye and vision problems, neurological damage and more).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Kamada previously reported positive preliminary data from the extension portion of its Phase 1/2 clinical trial of AAT to treat pediatric patients newly diagnosed with T1D.&#160;&#160;That preliminary data showed that at approximately 26 months from diagnosis and approximately 10 months following the last AAT infusion, 60% of study subjects who participated in the extension portion of the trial had peak C-peptide levels greater than 0.2 pmol/ml, which indicates a functioning beta cell capacity and is considered to be a higher percentage than would be expected without intervention.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In addition, patients continued to attain HbA1C targets according to International Society for Pediatric and Adolescent Diabetes standards, with an average HbA1C of 7.5%, with75% of the patients attaining HbA1C levels even lower than 7.5%, which is the clinically desired level for glycemic control in pediatric diabetic patients<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">,</font> who usually demonstrate a more severe or volatile form of disease compared with adults.&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About Type 1 Diabetes</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">T1D is an autoimmune disease in which the pancreatic beta cells responsible for insulin secretion are attacked by the immune system. In the absence of self-produced insulin and the concomitant glycemic control, there is a need to supply extraneous insulin in order to regain glycemic control and prevent future disease complications that include heart disease, blood vessels disease, nerve and eye disease, infections, hypoglycemic events and many more ailments.&#160;&#160;According to the U.S. Centers for Disease Control and Prevention, there are more than 10 million diabetic type 1 patients worldwide, with more than 100,000 newly diagnosed each year.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About Glassia</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Kamada AAT product, Glassia (Alpha1-Proteinase Inhibitor -Human)<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">,</font> is the first available ready-to-use liquid alpha1-proteinase inhibitor (Alpha1-PI) and is indicated as a chronic augmentation and maintenance therapy in adults with alpha-1 antitrypsin (AAT) deficiency.&#160;&#160;Glassia is administered once a week and is augmenting the levels of AAT in the blood.&#160;&#160;AAT is a protein derived from human plasma with known and newly discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue protective and antimicrobial properties.&#160;&#160;Glassia is approved by the U.S. Food and Drug Administration for the treatment of AAT deficiency.&#160;&#160;It is marketed through a strategic partnership with Baxalta Incorporated in the United States.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The scientific rationale for AAT to treat T1D is based on the fact that AAT has an adjunct anti-inflammatory activity that may modulate the immune system in a way that prevents it from attacking the pancreatic beta cells that would be destroyed by the autoimmune attack. Past studies have shown that despite having a normal serum level of AAT, the AAT of diabetic patients is inactive in this respect and, therefore, unable to cope with the developing inflammation in the beta cells. Additionally, a number of recent studies support the rationale for treating T1D early in the disease diagnosis or the &#8220;honeymoon&#8221; period, a period during which there are still some existing functional beta cells.&#160;&#160;It is hypothesized that AAT may halt pancreatic inflammation, thereby allowing the survival of active and operating beta cells that secrete insulin, a survival which may allow the patient to reduce dependence on external insulin and eventually decrease disease complications.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About Kamada</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a robust late-stage product pipeline.&#160; The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived proteins.&#160;&#160; AAT is a protein derived from human plasma with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. The Company&#8217;s flagship product is Glassia&#174;, the first and only liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration. Kamada markets Glassia in the U.S. through a strategic partnership with Baxalta.&#160; In addition to Glassia, Kamada has a product line of nine other injectable pharmaceutical products that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, India and other countries in Latin America, Eastern Europe and Asia.&#160; Kamada has five late-stage plasma-derived protein products in development, including an inhaled formulation of AAT for the treatment of AAT deficiency that completed pivotal Phase 2/3 clinical trials in Europe and is in Phase 2 clinical trials in the U.S. and its intravenous AAT to treat type-1 diabetes, GVHD and prevention of lung transplant rejection. Kamada also leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing 10 complementary products in Israel that are manufactured by third parties.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cautionary Note Regarding Forward-Looking Statements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.&#160;&#160;Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions and results related to financial results forecast, commercial results, timing and results of clinical trials and EMA and U.S. FDA authorizations.&#160;&#160;Forward-looking statements are based on Kamada&#8217;s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions.&#160;&#160;Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, unexpected results of clinical trials, delays or denial in the U.S. FDA or the EMA approval process, additional competition in the AATD market or further regulatory delays.&#160;&#160;The forward-looking statements made herein speak only as of the date of this announcement and Kamada undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Contacts:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Gil Efron</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">CFO</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">ir@kamada.com</font></font></div>
</td>
<td width="88%">
<div><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Anne Marie Fields</font></div>

<div>LHA</div>

<div>212-838-3777</div>

<div><font style="DISPLAY: inline; TEXT-DECORATION: underline">afields@lhai.com</font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
&#160;</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img.jpg
<TEXT>
begin 644 img.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!F17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (   $Q  (    0    3@
M      !@     0   &     !4&%I;G0N3D54('8U+C P /_; $,  0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( $4
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
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M.IMT45FZSK.E>'M*O];UR_MM+TC2[:2\U#4+R58+6TMH1NDFFE<A411W)')
MZFN.$9U)1A",ISG)0A"$7*4Y2:48QBDW*4FTDDFVVDE<]"<X4H3J5)QITZ<9
M3J5)R4(0A!.4ISE)J,8QBG*4I-))-MI(TJ*X3X<_$SP-\6O#%OXR^'FOVWB3
MPW=7-Y9P:G:AEC>XL+A[6ZCV/AQY<T;J&(VN '0E2#7=UIB,/B,)7JX7%4*N
M&Q.'J2I5\/7ISI5J-6#<9TZM*HHSISA)-2C**DFK-&.%Q>%QV&H8S!8BAB\)
MBJ4*^&Q6&JPKX?$4:D5*G5HUJ4I4ZM.<6I0G"4HR333:"BBBL3H"N;\8>+=
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MXF>$!XO_ &6M/\4^++V#0+:6[@LM:UF+Q"#J!\0R6LBBXO+&4"73M-NLVEQ
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M7-ZI8 ^7$1]/V=O+VVTVSN]1O98X+33[6XO;F:5@D4<%K"\\K.[$*JA$/)(
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M.@3>*OC;K%O\/](MA_K/)NXI;F]O .T5J8+=97Z+YRY///P)_P $79+\:?\
M'ZVB>9M#B\56!@4@FW2<0RB,1G&U6:$ E5(W#D@\5[I\5OVBO VG_MLZ=%XW
MD\1S>$?@=X2NX;2WT#PSJGB0'QWXFEA:YEN1I5O.UNUE8V%JT'G[3_I#[1S7
MMYCP4LB\7>(,%D&$JXO!\*\_$V"P5.G4Q%6+AA<-C\KP"A%.=3DS/%X+"ZVD
MZ$93D[IGSN5>(4N)? GA7,>*,?1P&/XV=+@_,,QJU*>$I34\;BLMSK,_:3Y:
M=+VF38',,9?X5B9*G%--(\B_X)+^-M1\&:Q\9/V8?%DR6^M^"-;N[_3K69F5
MFFL;YM,U6TLE8#>JR^;>-M 4QJ9 2#7[;5_-3\0OC7X0\"_\%"/!7QW^&3:_
MI?@KQMJNG:=XF;7_  ]JGAJ!#JT*:7KCM#JD-NURS^;->^9\R1R?,#Q7]*%O
M<0W=O;W=NP>WNX(;JW<'(>"XB6:%P>X>-U8'N#FN#QNRFM#/<HXME@ZN!CQK
MDN$S7%X6K3E2GA,ZH4J6%S?"U(22<9QK1IUFGJ_;-[6<O2^CIGF'GPWGW T,
M?2S&7AWQ%CLDP.-HUHUZ>.X>Q-6IC<AQE*I&34Z<L/.KATUHEATKWO&,U%%%
M?BI_0P5_*S_P7OU2[E^.GPIT9W!L;+P##?P)@[EN+RXO$G8G."&5%P,#&.M?
MU35_-+_P7W^'5S'J_P %/BI! \EK=6>H>$]2N5!*6SVA::PCD/13.TSB,'!;
M!Z\5^Y?1SQ&'P_BOD:Q#2>(PF;8;#N5O]YG@:LX13;5I3A3J1C:[;:BE[Q^"
M?27P^(Q'A#G[PZDUA\9D^)Q"C?\ W:GF-&$V[;QC.I3G*^B47)_"?SS:#_Q]
M#ZK_ #%?=W[,7@"Y^)_Q:^'W@JW16CU;7;5[]Y WD1:7IX_M'4Y)V4'9&+&U
MG&YL+N*C/(KX1T'_ (^A]5_F*_8C]BN"#X:_"CXZ_M$WX1+S0O#,?PZ\#I<;
M56[\3>,9%BN)[(L,M<V.DVFI LARF_U(-?WGQYF-7+<CQM7#?[]B?99=ER[Y
MCF52E@L$_P##"O7A5GT5.$Y2M%-K_/KP_P NHYGG.%I8O3+\+*MF>:2[99E=
M)X_'+I[U3#X>=*GU=6I"*3DTG^I/[:OQ>U#0O"OPWTSX."PL_ACXZM+?POJG
MBRQ0#5=8?PEJ?]AW7AZ24 ^3IT45@HVAR)E<X5<Y-CX\_&Y? OQ530Q\.O _
MB":V\$^#YXM:UG3S-J;/<Z<TA$TO(ECA"[8D(& <9KY(_9[N9OC1^RE\0?AM
M<R->>*_A1XGT_P")'ASS29;J71[F_M'U33[!269Y9IH[F:<)\V)68YSSZ1^V
M!;RVGQ\NK6==DT'@?P3'*F<[7729-RY[XK^8LIX=RO!YS@>%,7AX5L1DW^MD
M,75<ZM/$YC3JUN&\3EN88FI3J0JU)5,!BZ5!^][)2I3A"$8I17[_ ,6<69YB
M^'<RXVR_%SP^'SZ7 ]3!453H5\)E56C1XKP>:Y7A*5>E4HTHTLSP5;$1:A[9
MQK4YSJ3FY2?6_M.ZY=^/= ^$?Q*M@+30=>\,?V>NB6BB/3=$UK3V*:A#;PQX
MC@\_Y7" 9(ZDFOD.OJ?X;1+\0_@7\1_AZY:;6?!3Q_$/PS"-SSRV]O*L&M6T
M(YVQ^7<Q2LB\$1D@<&OECD<'@@X(]"."/P-?<<+0A@<-C<CC%0>29AB,/2BE
M;FP.)E]>P%6^\KX?$*C.;;<JM"KS2<N:WX_QS4JYGC<MXGG-U%Q-E6%QE:;=
M^7,\#%97FM&VT+8O"/$TZ45&-/#XJA&$8T^2_HGPCOY],^)_@.[MU9I5\4:3
M$ K%3MGNHX7Y )^ZYSQR..]?KI_P44U_0],_90^,.F7^K:?::AJ/AYK;3[&>
MZBCO+R:2ZB$:6]NS>;(7*D JI'!YK\O/V:?#-QXL^-O@+2X$++'JRZA.^W*0
MQ6"-<%Y#@A%+(J!CQO90.2*_<SX@_ [X4_%6_BU'X@^#=-\47-O;I:P'4O.D
MBC@C=I$46XD$!*LQ(<QE^?O5^.^*V;95E?'O!&/Q_P!9E#)80S2O3P4*,\35
M5',J-?"T?WU6E3A&K/"U4ZC<I0BW)0EHC^BO /(\[SKPO\2<LRMX.G4XAKRR
M7"ULRG7IX2@Z^4U</C<1?#T:U6K.C3QF'G&DHQC.45%U(ZM?G5_P3^\$_#+X
MX_L ^'OA#XRDTS5X[G5O'$6JZ2EQ;G5])>ZU=Y;._AB;=-:W"(1/;3!0#@')
M&:^._!7BOXG_ /!+WX_3^ ?&,FH:_P#L\>-=3=K'4_*=T^Q"3;!JEHI<Q6VH
MV*RJFH6H?$\;&1'9DV']SO ?P ^#_P ,-3?6/ /@?2O"VH2(8Y9M+\Z!)58%
M3YL"R>3(<$@,\;,!T(XQTOQ ^%_P_P#BGI=OHWQ"\)Z-XKTZUN5N[:WU:SBN
M#;W"JZ;X)67S8MRN0ZHZJ_!8$JI'R%/Q1RN/$/%L,9E^/SG@3C7'8W,<TR#&
MO#TL7@,?C*U3$0QV5UH5*U*EC<%5E%4J]Z:KTXI58*<(27Z75\&,XEPKP+4R
M_-,LR'Q+\.\NRW*<FXFRY8JM@,SRW+Z%'"U,NSJA4I8>M7P&8485'6P_+5^K
MU9R=&I*%2I!_$_[9G[57PZTS]FN^G\#>-M"UC4OBW!8>$O#IT_48)+JWM/$L
ML%K?:E<1HYFLAIUI.\DQF1&0JRXR#CZW^#7A#P1X9^&/@KPSX8_L+5M,T+P]
MIEHMY9+8WBS2-;K-++++%YH,LDCN268DXR><UP9_8V_9D,:1-\'_  HT49)C
MC-JYCC+')*(7*H2>25 )/->R>!OASX,^&VGSZ3X*T2'0M.N)$EDL[>6XDA#Q
MJ4C\M)I9!$JH2H2,*N.U?%YQFW"_^K6%R3A]Y]3K4<WQN:8FKF%' PACOK%+
M#8;"0JRPN)E*$LNPU&K"FU3G&M4Q->=J*DHK]!R#).,O];L;Q%Q1'ABM0Q&0
MY=DV$HY77S&I5R[ZK6Q.,QU2C'&X.$*L<UQE>C*LG4IRH4L%AH)UW%RE^'?_
M  4J2R^!_P"U'\"/V@O"-WIUMJB7\-KKFG6$\,<UNVD/$+BYOK6'$B&ZL[R8
M NG[PQ@'U'[)#X^?"J3X:I\2G\;^'%T&X\,'7?,;5K$7&'TTW36AM_/WB]#$
MH;;!EW\8)JIXR_9J^!WQ!UR\\2^-/AYHGB/6[Z3S;F^U1);F1GVJF45Y#'%E
M54$1*@.!D5B']D;]G,Z>-)/PL\/'2Q,;@:>4G-F)BNTR"W\WRMQ&.=O7FO>S
M;BOA'B#AS@G*LVAQ"LRX5PM3 8G,</A\OFL=EU7$?688**JXR,X+ MRHX6M)
MR<H2G*=*,I67S61\$\=<+<6>(F=Y)4X5EE'&N-HYGA<IQ6*S2G_9V:T,)#!U
M,QG*CE\X3>8QBJ^,PU-14:D(0IUI*/-+Y]_X)T^,?!?C/]GBYT^WUFQU.\O_
M !OXU_MG2;NX@^UR_P!HW*,R_8R_FO:W%JP",5^<!\=*_*'Q_P#"/XH_L\_M
MJ>)O@I\*)[S3/#'[0OF:+93QQR&%O"GB:X6YU.9%B(2&71W^TV]JV\^3%AR!
MG%?T!^"OV=?@O\.=6BUSP/X"TCPUJ<+%DN-,\^W4L05W/"DHAD8 D R1MC)Q
MSS7=:IX \':UXMT#QWJF@6%[XL\+VU[::#K4T0:[TZWU&,17<<1/RD2(,*6!
M,1RT95CFO2RWQ0R_(>*>+LVRW XS'Y)Q7@L:ZN49K3PK5#-'.6*RJO*,*E6C
M7IY?C%"U1QA-T9U$J3G&#?D9QX-9KQ/P7P)DF;YE@,MXCX(S'+E1SW)*N,3Q
M.2J%/!YYAH3JT:.(P]7-, ZB=+FJ4HXBE2;JNG.=O'OB!8^"?@W^S3XC\$_V
MII>@Z5X>^$NO:-IL6H7EO:R71@T"[B=HTD9&N)Y[IVSY:L[R.%Y8BOS0_P""
M.OC?PE9^"_BSH-]K^EZ?JI\2V.HQV=_>06DL]G<B\6.6W$[H9@"A\P("4RN[
M&X5^NGQ#^#GPU^*QLC\0O"MAXG73H9+>TBU!IF@CAEE,TB- DBQ2;I#NS(C$
M'H17GMA^R+^SEI4XNM+^%?A[3;D J)[!)[.;:PP5\RWEC?!],XSS7CY/Q=P]
M1X)XHX;S9Y[6S/BG,LOS3$YA0HX*='#8C+L14K1]VKBH5<3]9]K-UIR=%PD_
M=C*WO>]GO O%.(\1>#.+<D7#.'R;@O*LSR?!Y7B<1F5+$8O"9IA:&'E>6'P-
M2A@_J:HP6'A!8B-2$+3<'+W?DOXW?$/P+\8OVS?@1\%Y/%6@3>%OAVFI_$KQ
M#(=1MGLKGQ3IEG+/H>D2/O-K</'(+>8Q-(620%0C.-I_2J72?#=W9R_:M.TF
M73+FWD%RQMK3[/)92(1-F0)L\IH2V6SMVY.<5X/'^R'^SC%>_P!I1?"OP]'J
M/F^?_:"+<)?&;.XRF[683F0GEF,FXG))KWQ=$TQ-%/AY;8#2&T^32S:;Y,?8
M98F@D@\PMYN&B=EW;]XSD-FO XDSC)<;A>&\%D<\XH8;)<N6"K0QE+#4G4Q%
M7%U\9C,QI/#8FI^^Q-7$<OLII>SAAZ,56DE=?3\(Y#Q#E^-XMS#B2GD.)Q?$
M.;+,</4R^MC*ZI82C@<+E^ RFNL9@Z7[C!4,*Y>WIW=6IB:\O80OK_/K^R;\
M0M$_9;_;Z^+OP>O/$.F1_#WQUJNHVB:HE[$-*AU$7#:KX?A296-JD2K>7,#R
M>:@3RE7D\#[/_P""L?B7P[/^RAJ^FV^NZ5<:AJ.N^&IK"SM[ZWFN;N$:G9S^
M=!%&[.\)@'G+*!L:/Y@2.:^N9/V._P!FF:8W,_PD\,SW3,&:ZFAEEN6<=':X
M>0S,X_OERWO6WKW[+_P'\4&T/B'X=:-K L+*STZRCOS<W,5M9V%NMK:0Q12S
M-&@A@18U95#%1R2:_0\?XB<(X[CCA+C>6$S^..R*ADZS>/L,N3SG&Y+3I4Z.
M-NL9;#SQ4*:IUXOVO)"E3Y')W9^697X5<=Y;X<<<^'4<=PO++N)<3GSR*?UG
M-FN'LNX@J5*M?+W%X"^+IX*I4G5P\DZ+JU*M7G4(\J/ /V#OBY\,5_9+^#VG
M7'COPO8W_ASPO_9FM6>H:S8V-U87D%[=2R)-!<S1R*NR>,J^W:Q. :\C_;%_
M:H?XB^&]1_9U_9EL+OXF^._B '\/:_KFAPS3>'O"^D3E1>^?JJ)]G:YF4A<K
M(J1HK,K.WRU]?1?L<?LRP%C#\'_"<>XJ75;1A')L.Y5ECW[)4!YV2*RGG(YK
MV_PMX%\%^![4V?@[PEX;\+V[*%DCT#1=.TKS@#D>>UC;0/,1ZRLYKYBKQ-P7
MAN*<;Q;A<KSG-\76S;%9S@LLS>>"PF6X;'5\3/&47BYX.>(Q&/HX7$3YXT(_
M4U6]G"-6HX2E%_84>$/$'&<&9?P-CLYX?R+ 4,CP/#^89SD5/,,?F^+R[#8*
ME@*\,#3S"GA,)EF(QF%I.G/$S_M"5'VM25&FI1A-?%_[//PQ\#_L"_LUWG_"
M9^(=,CUR/3K_ ,7^+KV>XCMSJ>M+;/<)HVG"0B6[$$@6PMI-H9W?E%'6O_P3
M_P#^$=\6_"K7/B?>7FCZUXL^+?C37O&6JB1K2YU2RLVF2TT[3KF%S)/"MI;P
MJ0K  &3=QNP/KGXA?"'X<?%:*RM_B%X6T_Q1;:>'%K;:B)'MX][;VS"KK'(=
MPW R*Q! P1BLSP'\"?A/\,+\ZEX"\':?X8NF@FMV_LV2YBMVBGV^:#:>:;8N
MVQ?WGE;P!@,!7)C>+,#FN3<1U<RQ&;U>+>)LUP^99CCH4,(L!.CA)8BI2RZ%
ML1#$4Z%2O5HUIRC"U/ZK0I1HRC3C)]^7\#YEDO$'"5#*<+D5#@7@[),5E.59
M;/$8Z69T\3CHX.G7S6HI86IA:V(AAJ&(P\(3JJ526,Q->>(A*K*!\&_\%6_A
M=X;\3_LYGQ/!+I&E^*OA[KFGZ[HD):ULKB^AN)ULM01 -DLWDVTKS)&BN3(H
M^[UKVG]@/]H#1OC3^SQX"^VZ[I\_C7P]8MX8UW39+N%=4GN-(PJ7HLF<SF"6
MV>)4<*P(B/-?3'Q!^#?PT^*IM/\ A8/A2P\3K8H8[6+43,\$:%MY!@618G.[
MD,Z$@]#7/^"/V<?@E\-];B\1^!OA[H?AK6HE9$OM,B>"3:RE2KA7V.,$\.K8
MK>7%F18SPWPO!^94\VK9MEF<8K-\IQT*6$>&PBQ=&-*OEK<\2J\\)B*B^LSJ
M*$9TZKTI348G+#@CB7 >+F,X]RBID6'R/.,AP.0Y[EE2OCHXS'RP-?VV&S>*
MIX-X:&.PM)O"4J,IRIU:$?>K4G.2/;:***_,S]@"OCS]NS]FRT_:F_9P\<?#
M=(4/B6&S?Q#X*N& S!XGTA&N+!2<$E)]KP&,$;G=,]!7V'1G'.<8YSZ?_7KT
M<HS7&Y'FF7YSEU5T,=EF,P^-PM5?9K8>I&I#F7VH2<>6I':<)2B]&>9G.48'
M/\IS+),SHJOE^:X/$8'%TG]JAB:<J<W%])Q4N>G+>,XQDM4?YTS^'M8\*>*M
M6\+Z_8SZ;KFA:E/I6IV%RACGMKRUG,,L<B, 5.Y<C(Q@\5^K/Q7OK?X>? #X
M _ K3KBU>_O;!_BOX^CM9DG:/7=?A4:18W$D3$"33[::[5HGY3S<8%?K!_P4
M4_X)B:?\>[J\^-?P1L;/3/B[!#YGB+0@/LFG^-X+8%DE#1IY<.N(N8XY'7;=
M#:CNA^>ORI\'?%?P#\+K:'P/\;OV,_"NM>-] 4:7>ZOK-WJFD:I=O9_NC)=^
M>;B.ZER.9;>0PG(V8%?Z#9=XAY;XD99P_G6486MC\?D^)EBLVX8H8C+J&.P^
M8O!3PM'$7S'&X.%; 49UJ];#UJ7M/:3]BY*E5HS@O\X\T\-\S\,LPXFR+.L7
M0R_+LYPJPN3\58C#9E7P&*RSZ]0Q-?#VRS 8VI0S"O"AAZ.)HU%35."KJ/M:
M5:%0]"_8.^)5K\-/CMX3N]8EB3PUXBE_X1KQ$MT5^Q?V?JG[@SW2N0C+;LP=
M2?NGD=*^NOVV-1T_5/VEO$EYI=Y:WUD_A[PRL5Q9S1SP';8SC8LD3,N4& RY
MRO>OGGP_^T;^S?,Z&V_8V\%VC?+AH_$-V2#R003$",8R#UKW'2/CU\#;XK*?
MV7O"ZR%!\\FO7<SD!3@%Y(V8A02 "W Z5\UF>&S%\74^+5PGG='$_P!BU<GK
MX9XSAR4*T9XJAB*>(=2.=MQJ4E2=%QY'SQY+M>S,J6,RA<!UN!:G'/#E7"RX
MBH9_A\9]0XM53#RIX2OA:V$]F^'6ITJTJT:\7SQ]G-5&HR]HVN5^!/C$>"_B
M;X<U"YF\O2-2FET#7D)Q'/I&M0R6,\<IZ!%EEAF)/ \H$\"N8^)7AZ/PIX\\
M5:#;R0S6=CJ]U]@F@E6:*2PG<SV;K*A*MF"1,D'&>*]LD^,_P;F0Q6'[,WA2
M.\?Y;=SJ=U<!93]P^2B*\AW8PJD$]J]C^ W[)?B#XK^(5^(/Q \/_P#")^ I
MKE;VTT.-94?5(5(*6MM%(SRV]A\HC=YV#,-P5 ,$\>-X@PN15\;Q+GV$Q.04
M/[-IX.>'Q6(RVO6S*O0KSK8582E@<=B9SQ%-5L12:E!)PJ*4IPA2.3+>$\=Q
M1A<MX-X7QV#XJQ7]L5<PIXO 8;.<-A\EPV*PU+#X]X^MF>68.E2PE6>&PE92
MA-R52C.,*=2I72C[/^P)\%Y=&TO4/BUKMJT5YK4']F^&HY4QC2RRS75^-P!S
M/)' L#KP4\P9/-?2WQH^.>J?";X@?"7PY-9>$(O"GQ$U+4-.U?Q+XEUJYTF7
M06L(#/YD 7;93"8;447#K\QQ7T)I]G9Z58VFFZ?;16EC8P1VUK;0J$B@@B4*
MD<:*H55 '0 <Y-?-'QL^%_C'X@?%'X+>(=,T+PMK'A'X?ZKJ&H^(;?7[]!/=
MKJ-N;8I:Z=-IUW!/]EXE'F.OFDE!MQD_RW4S_#<6\98W..(HTE@<1A,T]EAZ
M^(5&&'A1RS%+*Z%&JYTX^WCB5AW!.].IB)2=2$J<I(_NC!\)XO@'P\RWAWA.
M6(EF>$QN2NOB\-A7B)XRMB<YP4L[Q>(H*G5E]5G@Y8M5%'EJ4<)",:56-6$)
M/F-0_:BN+SQ_\4/"/AF_^%LGAKP-\/H_%MKX\NO$MW=:>NHW"RI':ZQ]A9[.
M"TAF16E,,GGF+.!FO9[CXZ?#K0?[*TKQ7XQT&P\07=GH_P!K%I,\FEQ:CJ]J
M9K. 74A A-^8YI+&"X99YH4)"G:V/F?XD_L\>/=;\9?'*\\(^$? %IX8^*'P
MBE^'.E)_:4.DFSU*XM;B-M7N],MM&>'%M+,IC"R&1PN\.IX'R]XD\/\ C'2?
MB1X@N=1\):?XA7PMJ?PL1OA^=2OK*V\0^)?#ME=Z,-4MI?\ A'[RVUBVCBO)
MKNWN6N[)0(G\R%"HW_183ACA//:6'6"Q4,/*CEF$Q%;#X?&8*6,GB98;*:$_
MK-:M.=*C.>,Q.,]LIQH8:G.DO>H0;;^8Q_&/''#-;%2S# U<5'$YQC<-0Q6+
MR_,%E]+!T\9G6(@\'0P].%6O3AE^%P+HRIRQ&,JTJTO=Q$XJ*^X?V?\ ]I33
M_B!J'B/PQXR\1:'!XMC\>>*= \-:7:*+<WND:-=W"6F"S?O+I[2..9E^\Y8E
M!BNGUCXN^,_$WQ9\3_"#X5:;X;>^\#Z'IFJ>,/$?B:YO5MK&]UM99M)TS3K:
MR5EN))+>":2[><_NMH"@$UX+X$_9X^*.@ZEX;UB^\.>#+>XM_C-K7Q#OY8-;
M#7MGH.L3-=1V<4PTE7FO(!*;=[;>L>U.),8%>J>*_A?\0_A[\6_%WQU^#]CI
M'BF;QEX:M+'QC\.-7U%]$_M;4=!BF_LK4](UK[->I#>/#+);/;26P$K.#YBX
MKS,?@^$EG..EEU?+I/$Y96>58?$8JA+**6<T\;A:<85ZM&5*G0H5LO6*J898
MRI&@L4Z;Q%;V;/7RO'\=RX?RV&:X;-H1PF=86.=8O"8+%1SVOP_6R_%5YU<-
M1KQK5\3B</F<L'2QCP%.6*>"C5CAJ'MHM/?^%?[2&F^)K_Q)X*^)%KIW@7XE
M^#?% \(:SHJWKS:;J>HR0RW%A=:#<W.V:XAU*U@EN(86W2@I(H!"''H5Y\>?
MA)I_A^3Q1=>-]'CT2*_O],DNQ<(Y2]TJX>VU*)HE<R 6$L<@NV(VP+&[2852
M:^!?AOX5UWXTZ3JWQ)T2S2P^/-E\=/#'Q$\>^#O&=A=Z'8Z!#X=M]:TJ#PW8
MZ@]K<PWMHJ7_ )D5];%TNFC;?'$K@"/5_P!DCX^:AX)\4>$(;OP1:P^+]:^)
M^HZE]DU+R/*_X3W4-3O;=TEETJ4_9+-;](IK&)87E,;L)\.!7=C.$^#UFE2C
MC<XIY%.GBL%1QV GBJ<88>?U;VF93P+KTZU:I@9573GEF(E*K3KT*L>2I5BX
MU(^=E_&_'SR:C7R_(:O$M*KA,PQ&79I3P56I4Q-)8N-/)Z>91PU:A0IYE&@J
MM/.,-3A1JX;$TIJI2HU(RIS^IKWXY:[8^,/C3I3ZSX,MM%\(:=\)M3\&:IK<
ML]KI,\/CR36C=Q7]W:L9III8=-B%B( 097 ;*EJ]$M?VC/A#-J>O:-/XQTRT
MU'PSK%MX?U=)I/*@35[FVAN(K>"60J)1+YRQP_Q2/\H!;BOCC6/V;?CQJ^B?
M$#0[G2O 3Q^-O"?P@T!+D^(I2^GWGPNO;^8WJ*VD-QJ,-X45596B89+,#76_
M$3X62>'/"G[1,GCC2-!3PY\4M0\/ZGX3U+1(&U+Q/IOC,Z/I&D6%K:VD5C&\
M;6^JV3WD5XMPD;IND<1%C6%;(^#\34PV'CF%*I7J++L-3AE&(PDJLY_5^%\'
MB<1*ERU'7JSK5\YQ7U9>RE.IAJU2,^2HF=-#B/CW!TL5B9Y57HX>E_:F+K5,
M]P>.C1IP>*XQS#"86-=SHK#4:="AP_@UBW[2%.EC,/2J4U*BT?2OQ5^,\/@_
MX2_$7XD>"(M(\67GP^TO4[Z[TR^NKFULY+G2K9[JYL+BXLPT\,XC3&T#<KLH
M8"ODWQ-^V5X^LK36-/ET7P7HNK:)9?#'Q1=:UHFHWFMZ'%X>\=->?:M(U WV
MUK/Q!;+;J8XLA2A=L9 KV?5_@GXJ?]E#6OA'HCV&I^.O&/A*^M=<U?5KPZ?;
MWOB#Q):-'J>KW5PEM.X,:RI((3&Q+1F,,,[JR_&?P*\4:U\#/!?@G1O"?@BT
M\96VH>"Y_&&;Y8M.OH_#$?DR2MJ(TUIM29T4/##/$BHTC@,O).61QX*P<8TL
M=1P68N7$E;!4\5BL4J-2GEM%9=4CCZU&52--X.JJ684Z<:F']Z>)@JLTZ<(O
MHXCEXAX^3KY9B,?E48<(X?,*N"P>">(HULWKO-*<\LP^(C2G6CF%%U\KK5I4
M\5:$,)4=*#A4J->[1_'OX12>')_%2^-]';1K6_DTJXN!.GG)J4 /VBT%J&\Y
MI(0&DD 7*0CS6PG-0ZE^T)\&-(O]$TO4?B%X=M=0\16-MJ>CV<E_ )[W3[QV
MCM;N.,R!A#,ZLJ.P"DJPSD&OD+Q/^SO\;M2NO%!\.:9X&\.6'B;QSJVM7$-G
MK,?VF+1[[PX=$06\CZ(T,$L\X\^_MDBW36[O ES&QWUK_"S]G/XB^%O'>@>(
M_%_A7X>ZW::)\(S\/8[@ZC%=W2:A!=7=Y:WD,5SH[[%+RI$94E5X@S.HPF#A
M+AW@JGA*V*EQ ZLXTJM:E@:.99=]9E)T%*EAI5)4'2YX5[QE.'/[:#BX0IO?
M>'%?B)5QM#!+A94:<Z]"A6S.OE&:_4X06)Y*^+C36*5;V=3#-3ITZGLW0FI<
M]2LMOI+_ (:>^ WS?\7,\-Y%M=72+]NAW30V-PUM>?9UWYG>VE4B:./<T:X9
MP%(-=3??&CX7Z;)X7BO/&6CPOXR72W\.9N8RNHKK1B72"K!L(-2::);,OCSW
MD14R64'X.\,_LJ?%30XOAG'-X1^&L\O@/PI\9=%N[IM6BEDU6^^)\MN]A<N'
MT/[NA)"P5Y"TC-(?+,>*IZW^RU\?M7T'X;Z!$?!%C:^ K?X3':FLF5-0O/AM
MJ&DW<DER6T@3M]M.G%[4QRQK;1LD+)(5W'JGPMP)+$TJ=/BF-*A[2O&M5KYA
ME\VZ<<5C*%"=.-&@VG*C1PF,<)*\H8Q4'*G.E*;XX<9^)<<)6JUN"YU<3[+#
M2H4,-E6:07M98/+<3B:565?$I6CB,5CLOC4BTHSP#Q/+5IUH4U]_7/QF^&5G
MKESX=NO%NF0:G:)>-,LDJK:A].6-[ZV6\+?9WO+19H6GM5<S1B6/<HWKFI9_
M'/X57TMC;P^+]/2XU&^.FV=M<G[-<2WWV,:@EL89BLBR3V1%S;@KF>%EDCW*
M0:^1YOV<OC1JOPU\??![5KCX?#0-9N-4U3P_XSCBDE\1M<:G<6U])IUXAMUG
MM!)- ;6ZU".\=Y[78K1X0"J,?[+GCR#PIX,O=+\)_#GP_P",_"7C?2/$=UI&
MFZM?2Z=K\%EIITVYN+G7+NUEF@GV'=;6XM76.$+;[PBUQPX=X+Y)1J<2?OO;
MNA2=+%825&=.6'53#8VHZE*E.A3Q%:7L:V'4*L\!*G+ZU7C&K3:[ZG%?B'[2
M$J/"-\/]7CBJRK8+'PQ$)QQ7L<9EU&-*M6IXBKA:$?;T,6YT89E&M'ZEAIRH
MSC+ZJO?VE/@U8WOAJR?QC9S2>*]0U#3=):V!F22YTNY:TOE=DR$\BZ4P.#@A
MOF/R@FCPY\;O#,7@FQ\5>-?%'A:/^T=0U>"UG\-W$]Y8SVNG79A:2%92;ES:
M1M"-1E"F&WFD + ,N?F;X>?L\?%?P1<_#[5;C0_ &KWOAGQIXWUK5K.?40;>
M72_%U_/>H+&632I-EQ9^?L\O8 S+O#KD5C> OV;_ (Z?#F[\):]HT?@#4[K2
M+GQMI.K>&-9OI+K1IM"\2ZM%JMIJMG,^G-'#?P%IH+BR%J!,D<1:?!4+O5R#
M@E4\11P^?492A4O3K5LPP:>-]C4SE1HTJD<._J$:U.CEEZ]6G6I5)8J#_=\L
MDN>CQ/XB.KA:^*X9Q$8U*7+5HX?*\>XY?[>GPZY8BO2EBD\SE1JXC.%##4*N
M'K4H8.HKU7./-]G7'QE^'U]>1>&M!\8Z)=>*M:T/4=3\.6J3I/'=M:Z3-JJ9
M,;%6=+6/[4]L#YI@!? 7)'#?"[X^:'J?PT^&>M_$+7=.L?%WC/2Y;JYMK6-E
MA$W_  D6H:);RO&F[[%;SO!;Q0O-M1Y' !R<5\U:G^SE\?+KXL^&OB \O@6X
MLO"/B#7]3T_3+"\&BZ?/9:[X;O?#[0064.F226,\"7?F,[7$\3JA5(T! K*/
M[+GQH:R^%(L[3PKH?B/P$=.TJ3Q+8^*)9MVAP>,)O$&HQ7VF2Z1Y.M07ME<S
M6L%FQMVM)PLRS,2 -8\.\%+"T<.^(L'*6(^I8JMB5B\*Z^$K1H9Y"MA/:2I4
MIK"R;RFK74</5JJI)QIPJ3A[-83XI\1'CJ^*7">8QCA?[0P6'POU'&K"X[#S
MQ/#4Z&.]E"M6I_78+^W:.&=3%T:,J,>:I4HTY^T?Z?,"I*L,%25(/8@X(_ T
ME23,KRRN@PC2.R@]E9B5'X BHZ_*%>RNK:'[:]WZA4+_ 'C^'\A113$7;6Y9
M8IK7:-EQ]YP2LB\ ?*XY[ X/&?>OE?XY?LI_"/XSPN?&VA6]]<G)CU%8$BU2
M'"G 348#!=[<G)0R[6(&X'%%%=>"QV-R[$4\7E^+Q&"Q5&7-2Q&%K5*%>G+O
M"K2E&<=M;.SZG)CL!@<SPU3!YC@\-C\)6BXU<+C*%/$X>I%[J=&M&=.7SBS\
MZ_$O_!-+X::'=FZT/QSXIT^W=\)8FSL;N&)<\*LD\IG; XR[GWK7\+_L+^%5
MN4A?QUK[QKU TRP0L .A(F) /?'/H:**_28>)_'L\NDY\2XZI*$9QC.I#"3J
M6BXI7J3P[J2E;[4I.3>K;>I^08GP9\,'F<?^,/RV,:E6G*4*=3'4Z5YZR2I4
M\7&G"+?V80C%+1)+0^QOAA^R%\,?"=S;7R1RZK?QL'6ZU*".<JZD$/'#)))#
M&X/1T0,.QSS7VO911Z'I_P!AM 6C,7E9E.X*N-OR1@!%P.G!Q117YYF.:YGF
M]>6)S3'XO'UVOXF*KU*THIM>[!3DU"/:,%&*Z(_5,GR')>'L+' Y'E6 RK"1
ML_88'#4L/"4DK<T_9Q3J3[SJ.4V]7)O4I;F]?T'^%&YO7^7^%%%><>L&YO7^
M7^%,*J6W&.,M_>,49;V^8KNXYQSQDXHHH#?=#]S>O\O\*-S>O\J** &C"DLJ
M1HS?>9(XT9SZN54%B.Q8DBG;F]?Y?X444 &YO7^7^%1RQQS!1-'%,$=94$L:
M2!9$.4D4.I =#RK#YE[$4447:U6C!J^C5UV:N2;F]?T'^%&YO7^7^%%% !N;
MU_E_A1N;U_E_A110 ;F]?Y?X4;F]?Y?X444 &YO7^7^%&YO7^7^%%% !N;U_
CE_A1N;U_E_A110 ;F]?Y?X4H9LCGN/3U^E%% %VBBB@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
